Literature DB >> 8461923

Patients with anticentromere antibodies, clinical features, diagnoses and evolution.

P G Vlachoyiannopoulos1, A A Drosos, A Wiik, H M Moutsopoulos.   

Abstract

The sera of 1373 patients derived from a random population of 2627 individuals examined in a rheumatology outpatient clinic were found to be positive for antinuclear antibodies (ANA). Forty-seven of 1373 ANA positive patients (3.42%) presented a pattern of anticentromere antibodies (ACA), and of these 41 were followed-up. The predominant clinical features among ACA positive patients were Raynaud's phenomenon, arthralgias, scleroderma affecting the hands, feet, face and forearms, telangiectases and pulmonary involvement. There were 26 patients (64%) with limited cutaneous systemic sclerosis (lSSc), seven with primary Sjögren's syndrome (Ss) (17%), five with idiopathic Raynaud's phenomenon (IRPh) (12%) and three (7%) with other diseases. The lSSc subset was characterized by a significantly younger age for disease onset than for the IRPh patients. The Raynaud's phenomenon of lSSc patients lasted for many years before the onset of scleroderma, while their pulmonary involvement was mild and subclinical. The Ss patients with ACA were characterized by a lower incidence of parotid gland enlargement and anti-La (SSB) antibodies than described in the literature. Finally, the presence of ACA correlates with the clinical criteria proposed for the diagnosis of lSSc.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8461923     DOI: 10.1093/rheumatology/32.4.297

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  21 in total

Review 1.  Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis.

Authors:  T Dick; R Mierau; P Bartz-Bazzanella; M Alavi; M Stoyanova-Scholz; J Kindler; E Genth
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

Review 2.  Autoantibodies in Sjögren's Syndrome.

Authors:  Anum Fayyaz; Biji T Kurien; R Hal Scofield
Journal:  Rheum Dis Clin North Am       Date:  2016-06-21       Impact factor: 2.670

3.  The value of pattern capillary changes and antibodies to predict the development of systemic sclerosis in patients with primary Raynaud's phenomenon.

Authors:  Slavica R Pavlov-Dolijanovic; Nemanja S Damjanov; Nada Z Vujasinovic Stupar; Snezana Baltic; Dragan D Babic
Journal:  Rheumatol Int       Date:  2013-08-11       Impact factor: 2.631

4.  Primary Sjogren's syndrome with anticentromere antibodies--a clinically distinct subset.

Authors:  Dhiraj Gulati; Irving Kushner; Elizabeth File; Marina Magrey
Journal:  Clin Rheumatol       Date:  2010-01-19       Impact factor: 2.980

5.  Anticentromere antibody--clinical associations. A study of 44 patients.

Authors:  P Caramaschi; D Biasi; T Manzo; A Carletto; F Poli; L M Bambara
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

Review 6.  Autoantibodies to components of the mitotic apparatus.

Authors:  J B Rattner; G J Mack; M J Fritzler
Journal:  Mol Biol Rep       Date:  1998-07       Impact factor: 2.316

7.  Clinical significance and diagnostic usefulness of anti-centromere antibody in Sjögren's syndrome.

Authors:  Tetsutaro Kitagawa; Koichi Shibasaki; Shuji Toya
Journal:  Clin Rheumatol       Date:  2011-06-14       Impact factor: 2.980

8.  Clinical setting of patients with systemic sclerosis by serum autoantibodies.

Authors:  U Picillo; S Migliaresi; M R Marcialis; A M Ferruzzi; G Tirri
Journal:  Clin Rheumatol       Date:  1997-06       Impact factor: 2.980

Review 9.  Sjögren's syndrome--study of autoantigens and autoantibodies.

Authors:  John G Routsias; Athanasios G Tzioufas
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

10.  Prognostic value of Sjögren's syndrome autoantibodies.

Authors:  R Hal Scofield; Anum Fayyaz; Biji T Kurien; Kristi A Koelsch
Journal:  J Lab Precis Med       Date:  2018-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.